Rheumatoid Factor
Rheumatoid Factor (RF) is an antibody that is often elevated in autoimmune conditions, particularly rheumatoid arthritis. It is used to aid in the diagnosis of inflammatory joint diseases.
RF is a key biomarker for diagnosing rheumatoid arthritis and other inflammatory conditions.
Key facts at a glance
- Units
- IU/mL
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- Roche RF, Abbott RF, Siemens RF, Beckman RF
Rheumatoid Factor (RF) is an autoantibody that targets the Fc portion of immunoglobulin G (IgG). It is commonly found in the blood of individuals with rheumatoid arthritis, an autoimmune disorder characterized by chronic inflammation of the joints.
While RF is a valuable diagnostic tool, it is not specific to rheumatoid arthritis. Elevated levels can also be seen in other autoimmune diseases, chronic infections, and in some healthy individuals, particularly as they age.
The measurement of RF is often used in conjunction with other clinical findings and laboratory tests to support a diagnosis of inflammatory joint disease and to monitor disease activity over time.
Frequently asked questions
What does a high RF level mean?
Can RF levels change over time?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy